<DOC>
	<DOCNO>NCT01798706</DOCNO>
	<brief_summary>Primary objective : - To evaluate effect lixisenatide versus placebo period 24 week glycemic control , evaluate glycosylated hemoglobin ( HbA1c ) reduction , old type 2 diabetes participant ( T2DM ) inadequately control current anti-diabetic treatment regimen . Main secondary objective : - To assess safety tolerability lixisenatide compare placebo old T2DM participant ( include occurrence document ( Plasma Glucose PG &lt; 60 mg/dL ) symptomatic hypoglycemia gastrointestinal side effect ) . Other secondary objective : - To assess effect lixisenatide compare placebo 24-week treatment : - Fasting plasma glucose ( FPG ) ; - During liquid standardize breakfast meal challenge test : 2 hour- Postprandial Plasma Glucose ( PPG ) Plasma Glucose Excursion ; - 7-point Self-monitored plasma glucose ( SMPG ) profile ; - Body weight ; - Change total daily dose basal insulin ( take ) ; - Percentage participant require rescue therapy - Safety tolerability ; - To assess lixisenatide pharmacokinetic profile ; - To assess anti-lixisenatide antibody development .</brief_summary>
	<brief_title>Efficacy Safety Lixisenatide Versus Placebo Top Basal Insulin and/or Oral Antidiabetic Treatment Older Type 2 Diabetic Patients</brief_title>
	<detailed_description>Approximately 31 week include 24 week treatment period .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Inclusion criterion : Older participant , age 70 year , T2DM inadequately control current antidiabetic pharmaceutical treatment regimen . Signed write informed consent . Exclusion criterion : At screen HbA1c â‰¤7.0 % &gt; 10 % ( Acknowledging threshold 7 % may appropriate old participant responsibility investigator include participant base individual evaluation expect benefit well glycemic control versus risk hypoglycemia ) . At screen participant basal insulin sulfonylurea basal insulin meglitinides . At screen FPG &gt; 250 mg/dL ( &gt; 13.9 mmol/L ) . Type 1 diabetes mellitus history ketoacidosis within one year prior screen visit . Type 2 diabetes mellitus diagnose less 1 year prior screen . Antidiabetic treatment stable regimen initiate within last 3 month prior screen . Treatment within 3 month precede screen antidiabetic agent allow background therapy . Allowed therapy include metformin , sulfonylurea ( except glibenclamide &gt; 10mg , gliclazide &gt; 160mg ) , meglitinides ( except repaglinide &gt; 6mg ) , pioglitazone basal insulin follow local product circular label restriction study population . Participants approve investigational Glucagonlike peptide 1 ( GLP1 ) medication ( exenatide , liraglutide , lixisenatide others ) . History severe hypoglycemia associate symptom unawareness result unconsciousness/coma/seizure 6 month prior screen . BMI &lt; 22 &gt; 40 kg/m^2 . Malnutrition assess clinically investigator subinvestigator MiniNutritional AssessmentShort Form ( MNASF ) score &lt; 12 country ( judgment investigator prevail questionnaire score ) . Cognitive disorder dementia assess clinically investigator sub investigator Mini Mental State Examination ( MMSE ) score &lt; 24 ( judgment investigator prevail questionnaire score ) , neurologic disorder affect participant 's ability participate study . Participant glomerular filtration rate ( eGFR ) ( use Modification Diet Renal Disease ( MDRD ) formula &lt; 30ml/min/1.73m^2 ) . Participant severe uncontrolled disease , clinically significant abnormality identify physical examination investigational clinical procedure , judgment investigator subinvestigator , would preclude safe completion study constrain efficacy assessment . Laboratory findings time screening : Amylase and/or lipase : &gt; 3 time upper limit normal ( ULN ) laboratory range Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 time ULN Calcitonin &gt; 20 pg/mL ( 5.9 pmol/L ) . Clinically relevant history gastrointestinal disease associate prolonged nausea vomiting , include ( limited ) : gastroparesis , unstable ( i.e . worsen ) control ( i.e . prolonged nausea vomit ) gastroesophageal reflux disease within 6 month prior screen . History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease . Personal immediate family history medullary thyroid cancer genetic condition predispose medullary thyroid cancer ( e.g. , multiple endocrine neoplasia syndrome ) . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>